In the phase III GO-RAISE trial , @ patients were randomized to placebo with crossover to golimumab @ mg at Week @ ( n = @ ) , golimumab @ mg ( n = @ ) , or golimumab @ mg ( n = @ ) at baseline and every @ weeks .